A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
"The purpose of this study is to find out if ADI-PEG 20 (the study drug) can increase overall survival time for subjects with advanced hepatocellular carcinoma (HCC). The study will also evaluate the side effects of the study drug.
* Liver Cancer (Hepatocellular Carcinoma)
* Failure on prior treatment with at least 1 chemotherapy
* Cannot be candidate for surgery
18 - 100
Healthy Volunteers Needed
Duration of Participation
For as long as the treatment works and/or with no intolerable side effects.
Clinical Trials hotline: Phone 503-494-1080 or email@example.com